A new generation of weight-loss 'super-jabs' could help those who struggle to ditch the pounds with existing drugs, such as ...

The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a ...

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

The drugmaker says an oral version of Wegovy improved Alzheimer’s-related biomarkers, but didn’t delay the disease’s ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Novo Nordisk’s stock is experiencing a steep drop following major clinical setbacks and intensifying competitive pressure in ...

Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.

Novo Nordisk had hoped to repurpose semaglutide - the active ingredient in its Wegovy and Ozempic jabs - as a groundbreaking ...

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against ...

A shocking moment at the White House as Novo Nordisk executive Gordon Findlay collapses during President Donald Trump’s press ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Eli Lilly and Novo Nordisk are collaborating with Waltz Health to launch direct-to-employer access for obesity management medications. Waltz Health gave no information on the prices of GLP-1 drugs ...